Use of probiotics and probiotic-based immunomodulators as adjuvant therapy for Helicobacter pylori eradication


Cite item

Full Text

Abstract

At present, Helicobacter pylori (Нр) infection is the most common chronic bacterial infection in humans, the pathogen of which colonizes approximately 50% of the world’s population. Hp eradication is required to control complications of Hp-related diseases (gastric and duodenal ulcers). Nevertheless, a number of investigations have demonstrated widespread antibacterial therapy inefficiency due to Hp antibiotic resistance and patient non-compliance with treatment regimens. Due to the growing need to elaborate alternative eradication regimens, some researchers have drawn their attention to probiotics and immunomodulators derived from Lactobacillus in particular for eradication therapy in Нp-positive patients to enhance the effect of antibacterial drugs. The review analyzes the results of 10 meta-analyses of randomized clinical trials with a similar design, which were published in 2007 to 2015, and other clinical trials assessing the role of probiotics and probiotic-based immunomodulators as an adjuvant therapy for Hp eradication. The results of the analysis have established that Lactobacillus strain-containing probiotics, both monocomponent probiotics and those as part of multicomponent ones, when used as an adjunct to anti-Hp therapy, significantly increase the level of Нp eradication by 8.1—20.0% (p<0.05; Level of Evidence, 1A; Recommendation Grade A). The use of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (Licopid, a Lactobacillus bulgaricus-based immunomodulator) 0.001 and 0.01 g/day as an adjuvant to first-line triple anti-Hp therapy was shown to increase the level of Hp eradication by 7.1—8.9%. The intake of licopid 0.001 and 0.01 g/day during 7-day triple anti-Hp therapy results in the absence of recurrent Hp infection, as compared with 7- and 14-day treatment protocols without licopid, and leads to a significantly low incidence of Hp reinfection within 2—5 years after successful bacterial eradication, as compared with the 7-day protocol without adjuvant therapy with glucosaminylmuramyl dipeptide (p<0.05).

References

  1. Stark RM, Gerwig GJ, Pitman RS, Potts LF, Williams NA, Greenman J, Weinzweig IP, Hirst TR, Millar MR. Biofilm formation by Helicobacter pylori. Letters in applied microbiology. 1999;28(2):121-126. doi: 10.1046/j.1365-2672.1999.00481.x
  2. Chan WY, Hui PK, Leung KM, Chow J, Kwok F, Ng CS. Coccoid forms of Helicobacter pylori in the human stomach. Am J Clin Pathol. 1994;102(4):503-507. doi: 10.1093/ajcp/102.4.503
  3. Chaput C, Ecobichon C, Cayet N, Girardin SE, Werts C, Guadagnini S, Prévost M-C, Mengin-Lecreulx D, Labigne A, Boneca IG. Role of AmiA in the Morphological Transition of Helicobacter pylori and in Immune Escape. PLoS Pathog. 2006;2(9):e97. doi: 10.1371/journal.ppat.0020097
  4. Rosenstiel P, Hellmig S, Hampe J, et al. Influence of polymorphisms in the NOD1/CARD4 and NOD2/CARD15 genes on the clinical outcome of Helicobacter pylori infection. Cell Microbiol. 2006;8(7):1188-1198. doi: 10.1111/j.1462-5822.2006.00701.x.
  5. Hunt R, Xiao S, Megraud F, Leon-Barua R, Bazzoli F, Van Der Merwe S, Vaz Coelho LG, Fock M, Fedail S, Cohen H, Malfertheiner P, Vakil N, Hamid S, Goh KL, Wong BC, Krabshuis J, Le Mair A. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011;20(3):299-304.
  6. Go MF. Review article:natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002;16 (Suppl 1):3-15. doi: 10.1046/j.1365-2036.2002.0160s1003.x
  7. Vaira D, Gatta L, Ricci C, D’anna L, Miglioli M. Helicobacter pylori:diseases, tests and treatment. Dig Liver Dis. 2001;33(9):788-794. doi: 10.1016/S1590-8658(01)80697-6
  8. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection — the Masstricht IV/Florence Consensus Report. Gut. 2012;61(5):646-664. doi: 10.1136/gutjnl-2012-302084
  9. Mégraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs. 2004;64(17):1893-1904. doi: 10.2165/00003495-200464170-00003
  10. Yogeswaran K, Chen G, Cohen L, Cooper MA, Yong E, Hsieh E, Rowsell C, Saibil F, Tinmouth J. How well is Helicobacter pylori treated in usual practice? Can J Gastroenterol. 2011;25(10):543-546. doi: 10.1155/2011/647904
  11. De Francesco V, Zullo A, Hassan C, Della Valle N, Pietrini L, Minenna MF, Winn S, Monno R, Stoppino V, Morini S, Panella C, Ierardi E. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomized study. Dig Liver Dis. 2004;36:322-326. doi: 10.1016/j.dld.2003.12.015
  12. Минушкин О.Н., Осокина А.П., Шулешова А.Г. и др. Отдаленные результаты успешной эрадикации Неlicobacter pylori у больных язвенной болезнью двенадцатиперстной кишки. Кремлевская медицина. Клинический вестник. 2012;1:123-126.
  13. Бураков И.И. Результаты долгосрочного наблюдения за больными язвенной болезнью, ассоциированной с Helicobacter pylori, после эрадикации микроорганизма. Эксперим. иклин. гастроэнтерол. 2002;3:45-48.
  14. Lionetti E, Indrio F, Pavone L, Borrelli G, Cavallo L, Francavilla R. Role of probiotics in pediatric patients with Helicobacter pylori infection:a comprehensive review of the literature. Helicobacter. 2010;15(2):79-87. doi: 10.1111/j.1523-5378.2009.00743.x
  15. Imase K, Tanaka A, Tokunaga K, Sugano H, Ishida H, Takahashi S. Lactobacillus reuteri tablets suppress Helicobacter pylori infection - a double-blind randomized placebo-controlled cross-over clinical study. Kansenshogaku Zasshi. 2007;81(4):387-393. doi: 10.11150/kansenshogakuzasshi1970.81.387
  16. Wang KY, Li SN, Liu CS, Perng DS, Su YC, Wu DC, Jan CM, Lai CH, Wang TN, Wang WM. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr. 2004;80(3):737-741.
  17. Nista EC, Candelli M, Cremonini F, Cazzato IA, Zocco MA, Franceschi F, Cammarota G, Gasbarrini G, Gasbarrini A. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment:randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther. 2004;20(10):1181-1188. doi: 10.1111/j.1365-2036.2004.02274.x
  18. Hamilton-Miller JM. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents. 2003;22(4):360-366. doi: 10.1016/S0924-8579(03)00153-5
  19. Saxelin M, Tynkkynen S, Mattila-Sandholm T, de Vos WM. Probiotic and other functional microbes:from markets to mechanisms. Curr Opin Biotechnol. 2005;16(2):204-211. doi: 10.1016/j.copbio.2005.02.003
  20. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis:the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155-168. doi: 10.1111/j.1365-2036.2006.03179.x
  21. Zou J, Dong J, Yu X. Meta-analysis:Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(5):97-107. doi: 10.1111/j.1523-5378.2009.00716.x
  22. Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication:a systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol. 2009;21:45-53. doi: 10.1097/MEG.0b013e32830d0eff
  23. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis:the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32:1069-1079. doi: 10.1111/j.1365-2036.2010.04457.x
  24. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47(1):25-32. doi: 10.1097/MCG.0b013e318266f6cf
  25. Zheng X, Lyu L, Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate:evidence from a meta-analysis. Rev Esp Enferm Dig. 2013;105(8):445-453. doi: 10.4321/S1130-01082013000800002
  26. Li S, Huang XL, Sui JZ, Chen SY, Xie YT, Deng Y, Wang J, Xie L, Li TJ, He Y, Peng QL, Qin X, Zeng ZY. Meta-analysis of randomized controlled trails on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr. 2014;173:153-161. doi: 10.1007/s00431-013-2220-3
  27. Dang Y, Reinhardt JD, Zhou X, Zhang G. The Effect of Probiotics Supplementation on Helicobacter pylori Eradication Rates and Side Effects during Eradication Therapy:A Meta-Analysis. PLoS One. 2014;9(11):e111030. doi: 10.1371/journal.pone.0111030
  28. Lv Z, Wang B, Zhou X, Wang F, Xie Y, Zheng H, Lv N. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection:A meta-analysis. Exp Ther Med. 2015;9(3):707-716. doi: 10.3892/etm.2015.2174
  29. Zhang MM, Qian W, Qin YY, He J, Zhou YH. Probiotics in Helicobacter pylori eradication therapy:a systematic review and meta-analysis. World J Gastroenterol. 2015;21(14):4345-4357. doi: 10.3748/wjg.v21.i14.4345
  30. Bhatia SJ, Kochar N, Abraham P, Nair NG, Mehta AP. Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. J Clin Microbiol. 1989;27(10):2328-2330.
  31. Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Im-munol Med Microbiol. 2002;32(2):105-110. doi: 10.1111/j.1574-695X.2002.tb00541.x
  32. Gotteland M, Brunser O, Cruchet S. Systematic review:are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther. 2006;23(8):1077-1086. doi: 10.1111/j.1365-2036.2006.02868.x
  33. Yang YJ, Sheu BS. Probiotics-containing yogurts suppress Helicobacter pylori load and modify immune response and intestinal microbiota in the Helicobacter pylori-infected children. Helicobacter. 2012;17(4):297-304. doi: 10.1111/j.1523-5378.2012.00941.x
  34. Kwon HK, Kim GC, Kim Y, Hwang W, Jash A, Sahoo A, Kim JE, Nam JH, Im SH. Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response. Clin Immunol. 2013;146(3):217-227. doi: 10.1016/j.clim.2013.01.001
  35. Sultana R, McBain AJ, O’Neill CA. Strain-dependent augmentation of tight-junction barrier function in human primary epidermal keratinocytes by Lactobacillus and Bifidobacterium lysates. Appl Environ Microbiol. 2013;79(16):4887-4894. doi: 10.1128/AEM.00982-13
  36. Yeung CY, Chiang Chiau JS, Chan WT, Jiang CB, Cheng ML, Liu HL, Lee HC. In vitro prevention of salmonella lipopolysaccharide-induced damages in epithelial barrier function by various Lactobacillus strains. Gastroenterol Res Pract. 2013;2013:973209. doi: 10.1155/2013/973209
  37. Garhart CA, Heinzel FP, Czinn SJ, et al. Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin-12 dependent but gamma interferon and inducible nitric oxide synthase independent. Infect Immun. 2003;71:910-921. doi: 10.1128/IAI.71.2.910-921.2003
  38. Becher D, Deutscher ME, Simpfendorfer KR, et al. Local recall responses in the stomach involving reduced regulation and expanded help mediate vaccine-induced protection against Helicobacter pylori in mice. Eur J Immunol. 2010;40(10):2778-2790. doi: 10.1002/eji.200940219
  39. Micu G, Stăniceanu F, Zurac S, et al. The influence of Helicobacter pylori presence on the immunophenotype of inflammatory infiltrate in gastric diseases. Rom J Intern Med. 2011;49(1):45-54.
  40. Fan XG, Yakoob J, Fan XJ, Keling PW. Enchanced T-helper 2 Lymphocyte responses:immune mechanism of Helicobacter pylori infection. Ir J Med Sci. 1996;165(1):37-39. doi: 10.1007/BF02942800
  41. Beigier-Bompadre M, Moos V, Belogolova E, et al. Modulation of the CD4+ T-cell response by Helicobacter pylori depends on known virulence factors and bacterial cholesterol and cholesterol α-glucoside content. J Infect Dis. 2011;204(9):1339-1348. doi: 10.1093/infdis/jir547
  42. Kido M, Tanaka J, Aoki N, et al. Helicobacter pylori promotes the production of thymic stromal lymphopoietin by gastric epithelial cells and induces dendritic cell-mediated in-flammatory Th2 responses. InfectImmun. 2010;78(1):108-114. doi: 10.1128/IAI.00762-09
  43. Конорев М.Р., Коневалова Н.Ю. Современные представления об иммунной системе ассоциированной со слизистой оболочкой кишечника. Иммунопатология, аллергология, инфектология. 2010;2:40-46.
  44. Karttunen RA, Karttunen TJ, Yousfi MM et al. Expression of mRNA for interferon-gamma, interleukin-10, and interleukin-12 (p40) in normal gastric mucosa and in mucosa infected with Helicobacter pylori. Scand J Gastroenterol. 1997;32:22-27. doi: 10.3109/00365529709025058
  45. Larussa T, Leone I, Suraci E, Imeneo M, Luzza F. Helicobacter pylori and T Help-er Cells: Mechanisms of Immune Escape and Tolerance. J Immunol Res. 2015;2015:981328. doi: 10.1155/2015/981328
  46. Versalovic J. Helicobacter pylori: Pathology and Diagnostic Stratedies. Am J Clin Pathol. 2003;119(3):403-412. doi: 10.1309/5DTF5HT7NPLNA6J5
  47. Rathbone BJ, Wyatt JI, Worsley BW et al. Systemic and local antibody responses to gastric Campylobacter pyloridis in non-ulcer dyspepsia. Gut. 1986;27:642-647. doi: 10.1136/gut.27.6.642
  48. Perez-Perez GI, Dworkin BM, Chodos JE et al. Campylobacter pylori antibodies in humans. Ann Intern Med. 1988;109:11-17. doi: 10.7326/0003-4819-109-1-11
  49. Dunn B, Cohen H, Blaser MJ. Helicobacter pylori. Clin MicrobiolRev. 1997;10(4):720-741.
  50. Serelli-Lee V, Ling KL, Ho C, et al. Persistent Helicobacter pylori Specific Th17 Responses in Patients with Past H. pylori Infection Are Associated with Elevated Gastric Mucosal IL-1β. PLoS One. 2012;7(6):e39199. doi: 10.1371/journal.pone.0039199
  51. Bagheri N, Azadegan-Dehkordi F, Shirzad H, et al. The biological functions of IL-17 in different clinical expressions of Helicobacter pylori-infection. MicrobPathog. 2015;81:33-38. doi: 10.1016/j.micpath.2015.03.010
  52. Циммерман Я.С., Михалева Е.Н. Состояние иммунной системы у больных язвенной болезнью ДПК и влияние на нее современной терапии и иммуномодулирующих средств. Клин. мед. 2003;1:40-44.
  53. Пинегин Б.В., Андронова Т.М. Некоторые теоретические и практические вопросы клинического применения иммуномодулятора Ликопида. Иммунология. 1998;4:60-63.
  54. Girardin SE, Travassos LH, Hervé M, Blanot D, Boneca IG, Philpott DJ, Sansonetti PJ, Mengin-Lecreulx D. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem. 2003;278(43):41702-41708. doi: 10.1074/jbc.M307198200
  55. Козлов И.Г. Лекарственные воздействия через рецепторы врожденного иммунитета. М.; 2005:1-16.
  56. Meshcheryakova E, Makarov E, Philpott D, Andronova T, Ivanov V. Evidence for correlation between the intensities of adjuvant effects and NOD2 activation by monomeric, dimeric and lipophylic derivatives of N-acetylglucosaminyl-N-acetylmuramyl peptides. Vaccine. 2007;25(23):4515-4520. doi: 10.1016/j.vaccine.2007.04.006
  57. Конорев М.Р. Влияние ликопида на персистенцию Helicobacter pylori в слизистой оболочке желудка больных с хроническими гастритами. Иммунопатология, аллергология, инфектология. 2004;2:33-34.
  58. Конорев М.Р. Применение иммуномодулятора n-ацетил-глюкозаминил-n-ацетилмурамилдипептида при проведении антихеликобактерной тройной терапии. Терапевтический архив. 2012;12:65-69.
  59. Конорев М.Р., Андронова Т.М., Матвеенко М.Е. Частота рецидива и реинфекции Helicobacter pylori после проведения схемы эрадикации первой линии с использованием иммуномодулятора на основе пробиотика в качестве адъювантной терапии: результаты пятилетнего проспективного исследования. Иммунопатология, аллергология, инфектология. 2015; 4:85-92. doi: 10.14427/jipai.2015.4.85

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies